ethyl 4-amino-3-hydroxy-piperidine-1-carboxylate | 84100-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-amino-3-hydroxy-piperidine-1-carboxylate
• 英文别名: Ethyl 4-amino-3-hydroxypiperidine-1-carboxylate
• CAS: 84100-53-8
• 化学式: C₈H₁₆N₂O₃
• 分子量: 188.227
• InChiKey: TVTJWRDQBQQKIX-UHFFFAOYSA-N

物化性质

• 沸点：
  312.5±42.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-amino-3-hydroxy-piperidine-1-carboxylate 在 戴斯-马丁氧化剂 、 三乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 ethyl 2-(phenoxymethyl)-6,7-dihydro-4H-oxazolo[5,4-c]pyridine-5-carboxylate
  参考文献：
  名称：

  Discovery of VU0409551/JNJ-46778212: An mGlu₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia

  摘要：

  Herein, we report the structure activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu(5)) positive allosteric modulators (PAMs). On the basis of its robust in vitro potency and in vivo efficacy in multiple preclinical models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, 17a (VU0409551/JNJ-46778212) was selected as a candidate for further development.

  DOI：

  10.1021/acsmedchemlett.5b00181

文献信息

• [EN] BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] COMPOSÉS BICYCLIQUES D'OXAZOLE ET DE THIAZOLE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
  申请人：UNIV VANDERBILT

  公开号：WO2012031024A1

  公开（公告）日：2012-03-08

  In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5"); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及新型的双环氧唑和噻唑化合物，它们是代谢型谷氨酸受体亚型5（"mGluR5"）的阳性变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法；以及治疗或预防与谷氨酸功能障碍相关的疾病以及mGluR5受体亚型参与的疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着对本发明的限制。
• BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：Conn P. Jeffrey

  公开号：US20130261107A1

  公开（公告）日：2013-10-03

  In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  该发明涉及一种新型双环氧唑和噻唑化合物，它们是代谢型谷氨酸受体亚型5（“mGluR5”）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；使用这些化合物和组合物治疗与谷氨酸功能失调相关的神经和精神障碍的方法；以及用于治疗或预防与谷氨酸功能失调相关的疾病和mGluR5受体亚型参与的疾病的方法。本摘要旨在作为搜索特定技术领域的扫描工具，并不限制本发明。
• Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders
  申请人：By Kolbot

  公开号：US20090137810A1

  公开（公告）日：2009-05-28

  The subject invention provides methods and/or processes for making stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.

  本发明提供了制备式（X）的立体异构化合物的方法和/或过程：其中变量如此处所定义的，并提供了用于安全有效地治疗各种胃肠道疾病的组合物，包括但不限于胃轻瘫，胃食管反流及相关疾病。本发明的化合物还可用于治疗涉及中枢神经系统的各种疾病。
• 4-(aroylamino) piperidinebutanamide derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0251417A2

  公开（公告）日：1988-01-07

  The use for the manufacture of a medicament for the treatment of diarrhea of a compound of formula wherein Ar is thienyl, halothienyl, furanyl, halofuranyl, pyridinyl, aminopyridinyl, thiazolyl, imidazolyl or a radical of formula and Ar1 and Ar2 are, each independently, phenyl or halophenyl; the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions; novel compounds of formula (I).

  用于制造治疗腹泻的药物的式化合物 其中 Ar 是噻吩基、卤代噻吩基、呋喃基、卤代呋喃基、吡啶基、氨基吡啶基、噻唑基、咪唑基或式中的自由基，Ar1 和 Ar2 各自独立地是苯基或卤代苯基；药学上可接受的酸加成盐及其可能的立体化学异构形式；含有此类化合物作为活性成分的药物组合物以及制备所述化合物和药物组合物的方法；式 (I) 的新型化合物。
• Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0076530B1

  公开（公告）日：1985-12-11